These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 16199245

  • 1. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 2. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group.
    Lancet; 2005 Aug; 364(9435):665-74. PubMed ID: 15325831
    [Abstract] [Full Text] [Related]

  • 3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, TARGET Study Group.
    Lancet; 2005 Aug; 364(9435):675-84. PubMed ID: 15325832
    [Abstract] [Full Text] [Related]

  • 4. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB.
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [Abstract] [Full Text] [Related]

  • 6. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B, Berenbaum F.
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.
    Mackenzie IS, Wei L, Macdonald TM.
    Eur J Clin Pharmacol; 2013 Feb; 69(2):133-41. PubMed ID: 22732767
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.
    Circulation; 2001 Nov 06; 104(19):2280-8. PubMed ID: 11696466
    [Abstract] [Full Text] [Related]

  • 9. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S.
    J Clin Pharm Ther; 2017 Feb 06; 42(1):27-38. PubMed ID: 28019014
    [Abstract] [Full Text] [Related]

  • 10. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM.
    Clin Gastroenterol Hepatol; 2006 Jan 06; 4(1):57-66. PubMed ID: 16431306
    [Abstract] [Full Text] [Related]

  • 11. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.
    Am J Cardiol; 2007 Jan 01; 99(1):91-8. PubMed ID: 17196469
    [Abstract] [Full Text] [Related]

  • 12. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
    Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, Murphy K, Devane D.
    Cochrane Database Syst Rev; 2020 Apr 30; 4(4):CD011459. PubMed ID: 32352165
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 30; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 14. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis.
    van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA.
    Arthritis Res Ther; 2015 Mar 19; 17(1):66. PubMed ID: 25879879
    [Abstract] [Full Text] [Related]

  • 15. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q.
    Am J Cardiol; 2002 Jan 15; 89(2):204-9. PubMed ID: 11792343
    [Abstract] [Full Text] [Related]

  • 16. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.
    Lancet; 2002 Jan 15; 364(9450):2021-9. PubMed ID: 15582059
    [Abstract] [Full Text] [Related]

  • 17. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018 Jan 15; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 19. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K, Krammer G, Mellein B, Richard D, Matchaba P.
    Gastroenterology; 2007 Jul 18; 133(1):57-64. PubMed ID: 17631131
    [Abstract] [Full Text] [Related]

  • 20. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.
    J Rheumatol; 2000 Aug 18; 27(8):1876-83. PubMed ID: 10955327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.